A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Icotrokinra (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms FRONTIER 2
- Sponsors Janssen Research & Development
Most Recent Events
- 11 Mar 2024 Results presented in a Protagonist Therapeutics Media Release.
- 11 Mar 2024 According to a Protagonist Therapeutics media release, positive results from this study presented at the American Academy of Dermatology (AAD) 2024 Annual Meeting.
- 09 Nov 2023 Status changed from active, no longer recruiting to completed.